---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-001103"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:26:36.978123+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silexion expands SIL204 development with dual-route plan; preclinical data support; H1 2026 human trials targeted

## Summary
- Expanded development plan for SIL204 combines intratumoral and systemic administration for KRAS-driven pancreatic cancer.
- Preclinical orthotopic model data show systemic SIL204 significantly inhibits tumor growth and reduces metastases.
- Toxicology and pharmacodynamic studies planned through 2025; regulatory submissions to Israel Ministry of Health in H2 2025 and EU in H1 2026.
- Goal to initiate SIL204 human trials in H1 2026 for advanced localized KRAS-driven pancreatic cancer.
- First-generation product siG12DLoder previously showed overall survival benefit in Phase 2, supporting the expanded approach.

## SEC filing metadata
- accession: 0001178913-25-001103
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/0001178913-25-001103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/zk2532912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-001103
- JSON: https://secwatch.observer/filing/0001178913-25-001103.json
- Plain text: https://secwatch.observer/filing/0001178913-25-001103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.